Compounding this effect is evidence that PD patients exhibit impaired cytochrome P450 2D6 (CYP2D6) function, the key enzyme responsible for the metabolism of most anticholinergic drugs which contribute to increased adverse drug events [102]. The gene discussed is CYP2D6; the disease is Parkinson disease.